Strategy Inc (MSTR) stock rebounds after $2.1B bitcoin buy — dilution risk and Feb. 5 earnings ahead

Strategy Inc (MSTR) stock rebounds after $2.1B bitcoin buy — dilution risk and Feb. 5 earnings ahead

New York, January 21, 2026, 11:08 AM ET — Regular session

  • Strategy shares climb in late-morning trading, despite bitcoin falling below $90,000 again
  • A recent SEC filing revealed a $2.13 billion bitcoin buy, financed through stock sales
  • Investors are eyeing the Feb. 5 results and any fresh buy updates as the next trigger

Strategy Inc (MSTR.O) shares climbed roughly 1.8%, hitting $163.18 by late morning Wednesday. Bitcoin slipped about 1% to $89,762 during the same period.

The bitcoin-focused company revealed it bought 22,305 bitcoin between Jan. 12 and Jan. 19 for $2.13 billion, pushing total holdings to 709,715. The purchase was funded via an at-the-market program, which allows selling stock at current market prices. This included roughly 10.4 million common shares. According to the filing, about $8.43 billion of common stock remains available for sale under that program. 1

It’s relevant now as the trade gets jittery once more. Volatility measures surged Tuesday following fresh tariff threats that shook stocks, Treasuries, and the dollar. That kind of environment usually weighs more on high-beta crypto proxies than on the main tokens. 2

Strategy shares dropped 7.8% Tuesday, ending the day at $160.23. 3

“Strategy remains to keep buying bitcoin, since halting now would send just as strong a message to the market as adding more,” said Nic Puckrin, analyst and co-founder of Coin Bureau. He warned a pause might suggest the balance sheet isn’t equipped to handle further losses. 4

Strategy, once a software outfit, has pivoted to become a bitcoin treasury play under chairman Michael Saylor. Traders frequently use the stock as a leveraged proxy to bet on bitcoin without owning the cryptocurrency itself.

The math works both ways: issuing stock can fund more acquisitions but risks diluting current shareholders, particularly when the stock is weak. Investors are also keeping an eye on whether recent buys near market highs quickly become paper losses as bitcoin falls.

Crypto-related stocks edged higher on Wednesday. Coinbase climbed roughly 1.2%, Riot Platforms, a bitcoin miner, advanced around 1.4%, and Marathon Digital jumped about 6.7%.

Strategy revealed a $17.44 billion unrealized loss on its digital assets for Q4, highlighting how volatile bitcoin can quickly weigh on reported results and sentiment. This paper loss was disclosed earlier this month. 5

Strategy plans to release its fourth-quarter results on Feb. 5, right after U.S. markets close, followed by a webinar at 5 p.m. ET. 6

For now, traders are focused on whether bitcoin stays under the $90,000 mark and if Strategy’s upcoming updates reveal increased buying alongside more stock being sold to fund those purchases.

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Oracle stock slides again as ORCL lags Nasdaq rebound after tariff shock
Previous Story

Oracle stock slides again as ORCL lags Nasdaq rebound after tariff shock

Ondas stock jumps again as analysts lift targets, even as tariff jitters rattle markets
Next Story

Ondas stock jumps again as analysts lift targets, even as tariff jitters rattle markets

Go toTop